Does Rallies show Form 4 insider transactions for MXCT?

Yes. Rallies tracks MXCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MXCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MXCT. It does not provide personalized investment advice.

MXCT (MaxCyte, Inc. Common Stock) Stock Analysis - Insider Trades

MaxCyte, Inc. Common Stock (MXCT) is a publicly traded Healthcare sector company. As of May 21, 2026, MXCT trades at $1.07 with a market cap of $113.55M and a P/E ratio of -2.49. MXCT moved +1.44% today. Year to date, MXCT is -30.97%; over the trailing twelve months it is -50.92%. Its 52-week range spans $0.64 to $5.20. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces MXCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MXCT stock inside the company?

Recent MXCT insider activity includes Swirsky Douglas J sold 10.14K, Swirsky Douglas J bought 50.00K, Masoud Maher bought 75.00K, Erck Stanley C bought 100.00K, and DOUGLAS RICHARD bought 80.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MXCT Key Metrics

Key financial metrics for MXCT
Metric	Value
Price	$1.07
Market Cap	$113.55M
P/E Ratio	-2.49
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$5.20
52-Week Low	$0.64
Volume	0
Avg Volume	0
Revenue (TTM)	$33.03M
Net Income	$-44.63M
Gross Margin	81.16%

Recent MXCT Insider Trades

Swirsky Douglas J sold 10.14K (~$8.27K) on Mar 17, 2026.
Swirsky Douglas J bought 50.00K (~$64.50K) on Aug 13, 2025.
Masoud Maher bought 75.00K (~$102.92K) on Aug 13, 2025.
Erck Stanley C bought 100.00K (~$137.22K) on Aug 13, 2025.
DOUGLAS RICHARD bought 80.00K (~$111.04K) on Aug 13, 2025.

Latest MXCT News

MaxCyte Q1 Revenue $9.7M; Core Down 25%, SPL Up 62%, $10M Buyback — May 12, 2026
MaxCyte Grants 375,000 Options and 187,500 RSUs to New CFO — Mar 31, 2026
MaxCyte Q4 revenue drops 16% to $7.3M, guides $30–32M in 2026 — Mar 24, 2026
MaxCyte Appoints Parmeet Ahuja as CFO Effective March 30, 2026 — Mar 23, 2026
MaxCyte Debuts ExPERT DTx Platform Processing 96 Samples in Three Minutes — Feb 25, 2026

MXCT Analyst Consensus

5 analysts cover MXCT: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.

Common questions about MXCT

Who is trading MXCT stock inside the company?: Recent MXCT insider activity includes Swirsky Douglas J sold 10.14K, Swirsky Douglas J bought 50.00K, Masoud Maher bought 75.00K, Erck Stanley C bought 100.00K, and DOUGLAS RICHARD bought 80.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MXCT?: Yes. Rallies tracks MXCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MXCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MXCT. It does not provide personalized investment advice.